Short answer
Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on August 11, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results and business update announced for quarter ended June 30, 2026.
Cardiff Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results and business update announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the financial details and operational update
- Investor focus: cash position, clinical-program progress, and financing outlook in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Phase 2 CRDF-004 supported advancing 30 mg onvansertib plus FOLFIRI/bevacizumab into a planned registrational program
- Confirmed ORR 72.2% versus 42.1% for standard of care, with PFS hazard ratios of 0.55 and 0.57
- FDA End-of-Phase 2 alignment targets Phase 3 initiation in Q1 2027, contingent on additional financing
- $10 million registered direct offering extends funding, with cash resources projected into Q3 2027
- NMS license-termination dispute creates material uncertainty around Cardiff’s rights to develop onvansertib
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cardiff Oncology, Inc. 8-K filings
Get the next CRDF 8-K as it lands
Follow CRDF for push alerts, or ask the research agent what this filing means.